Claims for Patent: 11,241,425

Summary for Patent: 11,241,425

Title:	Composition for treating mental illness
Abstract:	The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
Inventor(s):	Deaver; Daniel R. (Wilmington, NC), Todtenkopf; Mark (Franklin, MA)
Assignee:	Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:	17/071,236
Patent Claims:	1. A method of reducing induced weight gain associated with olanzapine administration in a patient suffering from bipolar disorder and in need of olanzapine treatment, comprising orally administering, daily, to the patient a pharmaceutical composition comprising: olanzapine; 10 mg of a compound, based on the free base weight and having the structure: ##STR00022## or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. 2. The method according to claim 1, wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt. 3. The method according to claim 1, wherein the pharmaceutical composition is a tablet. 4. The method according to claim 1, wherein the pharmaceutical composition further comprises lactose. 5. The method according to claim 1, wherein the pharmaceutical composition further comprises magnesium stearate. 6. The method according to claim 5, wherein the pharmaceutical composition further comprises lactose. 7. The method according to claim 1, wherein the bipolar disorder is bipolar disorder I. 8. The method according to claim 1, wherein the bipolar disorder is bipolar disorder I with a mixed or manic episode. 9. A method of reducing induced weight gain associated with olanzapine administration in a patient suffering from a manic or mixed episode associated with bipolar disorder I and in need of olanzapine treatment, comprising orally administering, daily, to the patient a pharmaceutical composition comprising: olanzapine; 10 mg of a compound, based on the free base weight, having the structure: ##STR00023## and a pharmaceutically acceptable excipient; wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt. 10. The method according to claim 9, wherein the pharmaceutical composition is a tablet. 11. A method of reducing induced weight gain associated with olanzapine administration in a patient suffering from bipolar disorder and in need of olanzapine treatment, comprising: orally administering daily to the patient 10 mg, based on the free base weight, a compound having the structure: ##STR00024## or a pharmaceutically acceptable salt thereof; and administering to the patient, daily, an antipsychotic, wherein the antipsychotic is olanzapine. 12. The method according to claim 11, wherein the compound is present as a pharmaceutically acceptable salt. 13. The method according to claim 11, wherein administering the compound and administering the olanzapine occurs concurrently. 14. The method according to claim 11, wherein the bipolar disorder is bipolar disorder I. 15. A method of reducing induced weight gain associated with olanzapine administration in a patient suffering from a manic or mixed episode associated with bipolar disorder I and in need of olanzapine treatment, comprising: orally administering daily to the patient 10 mg, based on the free base weight, a compound having the structure: ##STR00025## or a pharmaceutically acceptable salt thereof; and administering to the patient, daily, an antipsychotic, wherein the antipsychotic is olanzapine. 16. The method according to claim 15, wherein the compound is present as a pharmaceutically acceptable salt.